Performance evaluation of SARS-CoV-2 rapid diagnostic tests in Nigeria: A cross-sectional study
Open Access
- 15 July 2024
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 4 (7) , e0003371
Abstract
The COVID-19 pandemic challenged health systems globally. Reverse transcription polymerase chain reaction (RT-PCR) is the gold standard for detecting the presence of SARS-CoV-2 in clinical samples. Rapid diagnostic test (RDT) kits for COVID-19 have been widely used in Nigeria. This has greatly improved test turnover rates and significantly decreased the high technical demands of RT-PCR. However, there is currently no nationally representative evaluation of the performance characteristics and reliability of these kits. This study assessed the sensitivity, specificity, and predictive values of ten RDT kits used for COVID-19 testing in Nigeria. This large multi-centred cross-sectional study was conducted across the 6 geo-political zones of Nigeria over four months. Ten antigen (Ag) and antibody (Ab) RDT kits were evaluated, and the results were compared with RT-PCR. One thousand, three hundred and ten (1,310) consenting adults comprising 767 (58.5%) males and 543 (41.5%) females participated in the study. The highest proportion, 757 (57.7%), were in the 20–39 years’ age group. In terms of diagnostic performance, Lumira Dx (61.4, 95% CI: 52.4–69.9) had the highest sensitivity while MP SARS and Panbio (98.5, 95% CI: 96.6–99.5) had the highest specificity. For predictive values, Panbio (90.7, 95% CI: 79.7–96.9) and Lumira Dx (81.2, 95% CI: 75.9–85.7) recorded the highest PPV and NPV respectively. Ag-RDTs had better performance characteristics compared with Ab-RDTs; however, the sensitivities of all RDTs in this study were generally low. The relatively high specificity of Ag-RDTs makes them useful for the diagnosis of infection in COVID-19 suspected cases where positive RDT may not require confirmation by molecular testing. There is therefore the need to develop RDTs in-country that will take into consideration the unique environmental factors, interactions with other infectious agents, and strains of the virus circulating locally. This may enhance the precision of rapid and accurate diagnosis of COVID-19 in Nigeria.Keywords
Funding Information
- The World Bank - Regional Disease Surveillance Systems Enhancement (REDISSE
This publication has 29 references indexed in Scilit:
- Performance of a rapid antigen test for SARS-CoV-2 in KenyaDiagnostic Microbiology and Infectious Disease, 2021
- Scaling up COVID-19 rapid antigen tests: promises and challengesThe Lancet Infectious Diseases, 2021
- Performance and operational feasibility of antigen and antibody rapid diagnostic tests for COVID-19 in symptomatic and asymptomatic patients in Cameroon: a clinical, prospective, diagnostic accuracy studyThe Lancet Infectious Diseases, 2021
- Field performance evaluation of the PanBio rapid SARS-CoV-2 antigen assay in an epidemic driven by the B.1.351 variant in the Eastern Cape, South AfricaJournal of Clinical Virology Plus, 2021
- SARS-CoV-2 variants and ending the COVID-19 pandemicThe Lancet, 2021
- Field evaluation of the performance of a SARS-CoV-2 antigen rapid diagnostic test in Uganda using nasopharyngeal samplesInternational Journal of Infectious Diseases, 2021
- The coronavirus is here to stay — here’s what that meansNature, 2021
- Schistosomiasis in Nigeria: Gleaning from the past to improve current efforts towards controlOne Health, 2020
- Development and clinical application of a rapid IgM‐IgG combined antibody test for SARS‐CoV‐2 infection diagnosisJournal of Medical Virology, 2020
- Sample size estimation in diagnostic test studies of biomedical informaticsJournal of Biomedical Informatics, 2014